Abstract
Only radical resection can cure patients with pancreatic cancer (PC); however, adjuvant gemcitabine (GEM) doubles the postoperative five-year-survival. The best treatment of locally advanced PC is not established, but radio-chemotherapy followed by surgery may be considered. Fit patients with metastatic PC benefit from GEM, which is standard. The addition of the epidermal growth factor-receptor-inhibitor erlotinib prolongs median survival significantly by two weeks and one-year survival by 7%. Very fit patients might benefit by combining GEM with platinum or capecitabine, but evidence is not firm. Participation in clinical trials is strongly encouraged in PC.
| Translated title of the contribution | [Oncological treatment of patients with pancreatic cancer] |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 172 |
| Issue number | 18 |
| Pages (from-to) | 1373-6 |
| Number of pages | 4 |
| ISSN | 0041-5782 |
| Publication status | Published - 3 May 2010 |
| Externally published | Yes |